standard of care in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 (REV) 1.44 [0.59; 3.51]
1.44 [0.59 ; 3.51 ] FACCT Trial, 2021 (REV) 1 0% 254 NA not evaluable deathsdetailed results Dabbous HM, 2020 (REV) 1.98 [0.06; 60.39]
FACCT Trial, 2021 (REV) 1.04 [0.48; 2.26]
Lou (FAVIPIRAVIR), 2020 (REV) 0.89 [0.02; 50.23]
NCT04542694, 2020 (REV) 1.00 [0.02; 50.90]
Udwadia, 2020 (REV) 2.01 [0.07; 60.94]
1.10 [0.54 ; 2.24 ] Dabbous HM, 2020 (REV), FACCT Trial, 2021 (REV), Lou (FAVIPIRAVIR), 2020 (REV), NCT04542694, 2020 (REV), Udwadia, 2020 (REV) 5 0% 722 moderate not evaluable clinical improvementdetailed results AVIFAVIR, 2020 (REV) 1.89 [0.46; 7.82]
Lou (FAVIPIRAVIR), 2020 (REV) 0.80 [0.13; 4.87]
NCT04542694, 2020 (REV) 0.48 [0.24; 0.97]
Ruzhentsova T, 2020 (REV) 0.61 [0.43; 0.88]
Udwadia, 2020 (REV) 0.57 [0.36; 0.91]
0.61 [0.47 ; 0.78 ] AVIFAVIR, 2020 (REV), Lou (FAVIPIRAVIR), 2020 (REV), NCT04542694, 2020 (REV), Ruzhentsova T, 2020 (REV), Udwadia, 2020 (REV) 5 0% 597 moderate not evaluable clinical improvement (14-day)detailed results AVIFAVIR, 2020 (REV) 1.89 [0.46; 7.82]
Lou (FAVIPIRAVIR), 2020 (REV) 0.80 [0.13; 4.87]
Ruzhentsova T, 2020 (REV) 0.78 [0.64; 0.95]
0.79 [0.65 ; 0.97 ] AVIFAVIR, 2020 (REV), Lou (FAVIPIRAVIR), 2020 (REV), Ruzhentsova T, 2020 (REV) 3 0% 247 moderate not evaluable clinical improvement (28-day)detailed results Ruzhentsova T, 2020 (REV) 0.90 [0.78; 1.04]
Udwadia, 2020 (REV) 0.57 [0.36; 0.91]
0.76 [0.49 ; 1.17 ] Ruzhentsova T, 2020 (REV), Udwadia, 2020 (REV) 2 70% 318 moderate not evaluable clinical improvement (7-day)detailed results NCT04542694, 2020 (REV) 0.48 [0.24; 0.97]
Ruzhentsova T, 2020 (REV) 0.67 [0.45; 0.98]
0.62 [0.44 ; 0.87 ] NCT04542694, 2020 (REV), Ruzhentsova T, 2020 (REV) 2 0% 368 moderate not evaluable clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 (REV) 1.18 [0.86; 1.62]
Ruzhentsova T, 2020 (REV) 0.61 [0.43; 0.88]
Udwadia, 2020 (REV) 0.57 [0.36; 0.91]
0.76 [0.47 ; 1.23 ] FACCT Trial, 2021 (REV), Ruzhentsova T, 2020 (REV), Udwadia, 2020 (REV) 3 80% 572 moderate not evaluable hospital dischargedetailed results FACCT Trial, 2021 (REV) 1.14 [0.83; 1.57]
Udwadia, 2020 (REV) 0.71 [0.49; 1.03]
0.91 [0.57 ; 1.44 ] FACCT Trial, 2021 (REV), Udwadia, 2020 (REV) 2 72% 404 moderate not evaluable mechanical ventilationdetailed results Udwadia, 2020 (REV) 15.38 [1.21; 195.69]
15.38 [1.21 ; 195.69 ] Udwadia, 2020 (REV) 1 0% 14 NA not evaluable mechanical ventilation (time to event analysis only)detailed results Udwadia, 2020 (REV) 15.38 [1.21; 195.69]
15.38 [1.21 ; 195.69 ] Udwadia, 2020 (REV) 1 0% 14 NA not evaluable viral clearance detailed results AVIFAVIR, 2020 (REV) 0.26 [0.08; 0.81]
Dabbous HM, 2020 (REV) 0.75 [0.34; 1.66]
Lou (FAVIPIRAVIR), 2020 (REV) 5.43 [0.21; 139.89]
NCT04542694, 2020 (REV) 0.08 [0.02; 0.34]
Ruzhentsova T, 2020 (REV) 0.78 [0.56; 1.09]
Udwadia, 2020 (REV) 0.73 [0.51; 1.06]
0.57 [0.35 ; 0.94 ] AVIFAVIR, 2020 (REV), Dabbous HM, 2020 (REV), Lou (FAVIPIRAVIR), 2020 (REV), NCT04542694, 2020 (REV), Ruzhentsova T, 2020 (REV), Udwadia, 2020 (REV) 6 63% 696 moderate not evaluable viral clearance (time to event analysis only)detailed results Ruzhentsova T, 2020 (REV) 0.78 [0.56; 1.09]
Udwadia, 2020 (REV) 0.73 [0.51; 1.06]
0.76 [0.59 ; 0.97 ] Ruzhentsova T, 2020 (REV), Udwadia, 2020 (REV) 2 0% 318 moderate not evaluable viral clearance by day 14detailed results AVIFAVIR, 2020 (REV) 0.32 [0.06; 1.62]
Lou (FAVIPIRAVIR), 2020 (REV) 5.43 [0.21; 139.89]
Ruzhentsova T, 2020 (REV) 1.01 [0.95; 1.08]
0.89 [0.38 ; 2.09 ] AVIFAVIR, 2020 (REV), Lou (FAVIPIRAVIR), 2020 (REV), Ruzhentsova T, 2020 (REV) 3 32% 247 moderate not evaluable viral clearance by day 7detailed results AVIFAVIR, 2020 (REV) 0.26 [0.08; 0.81]
Dabbous HM, 2020 (REV) 0.75 [0.34; 1.66]
Ruzhentsova T, 2020 (REV) 0.95 [0.83; 1.09]
0.70 [0.38 ; 1.29 ] AVIFAVIR, 2020 (REV), Dabbous HM, 2020 (REV), Ruzhentsova T, 2020 (REV) 3 61% 327 moderate not evaluable ICU admissiondetailed results FACCT Trial, 2021 (REV) 0.70 [0.39; 1.26]
Lou (FAVIPIRAVIR), 2020 (REV) 0.18 [0.01; 4.75]
0.67 [0.38 ; 1.20 ] FACCT Trial, 2021 (REV), Lou (FAVIPIRAVIR), 2020 (REV) 2 0% 273 moderate not evaluable serious adverse eventsdetailed results NCT04542694, 2020 (REV) 0.16 [0.01; 3.29]
Ruzhentsova T, 2020 (REV) 0.49 [0.02; 10.97]
Udwadia, 2020 (REV) 0.97 [0.02; 49.70]
0.37 [0.06 ; 2.46 ] NCT04542694, 2020 (REV), Ruzhentsova T, 2020 (REV), Udwadia, 2020 (REV) 3 0% 511 moderate not evaluable adverse eventsdetailed results NCT04542694, 2020 (REV) 1.00 [0.54; 1.85]
Ruzhentsova T, 2020 (REV) 0.53 [0.26; 1.05]
Udwadia, 2020 (REV) 0.16 [0.06; 0.41]
0.46 [0.18 ; 1.21 ] NCT04542694, 2020 (REV), Ruzhentsova T, 2020 (REV), Udwadia, 2020 (REV) 3 80% 511 moderate not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-13 22:31 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 651
- roots T: 651
